M&A analysis: signs of life emerge
Some big deals in the second quarter have raised hopes that takeouts are back.
How to be different in in vivo Car-T
After Astra's EsoBiotec takeover the battle for uniqueness begins.
Astra gives in vivo Car-T its biggest endorsement
The company buys Belgium’s EsoBiotec for $425m.
Arvinas’s degrader disappoints
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
Vir shows up Sanofi
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
